Esperion Therapeutics, Inc. (ESPR)
ESPR moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How ESPR actually reacts to news — the realized, point-in-time move the market made, measured across 401 labeled events over the last three years with zero look-ahead.
ESPR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 355 |
| 30-min | 0.00% | 47% | 356 |
| 60-min | +0.00% | 50% | 356 |
| to close | 0.00% | 46% | 355 |
| Middle 50% of ESPR reactions | -1.81% to +1.58% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 401 |
Half of all Esperion Therapeutics, Inc. news events land between -1.81% and +1.58% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ESPR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.40% | 50% | +1.76% |
| Analyst downgrades | 21 | -0.16% | 29% | 0.00% |
| Coverage initiations | 10 | +3.10% | 70% | +1.65% |
| Rating reiterations | 77 | -0.69% | 38% | -1.65% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ESPR ranks against every other measured name →
That’s how ESPR usually reacts — get an email when it moves on news →Email me when ESPR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ESPR's baseline. Nothing else.
Recent ESPR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 | Press release | GlobeNewswire | — | — | |
| Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure | Press release | GlobeNewswire | — | — | |
| Form 15-12G Esperion Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Esperion Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Esperion Therapeutics, For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Esperion Therapeutics, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POS462B Esperion Therapeutics, | SEC filing · Form POS462B | SEC EDGAR | — | — | |
| Form POSASR Esperion Therapeutics, | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Esperion Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Esperion Therapeutics, For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +0.95% | |
| Form 8-K/A Esperion Therapeutics, For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.32% | |
| Form 8-K Esperion Therapeutics, For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.64% | |
| Form DEFA14A Esperion Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.64% | |
| Form 8-K Esperion Therapeutics, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | +0.00% | |
| Form DEFM14A Esperion Therapeutics, | SEC filing · Form DEFM14A | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Esperion Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.32% | |
| Form PREM14A Esperion Therapeutics, For: May 29 | SEC filing · Form PREM14A | SEC EDGAR | +0.16% | +0.00% | |
| Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 | Press release | GlobeNewswire | +0.16% | +0.00% | |
| Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.16% | +0.00% | |
| Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 | Press release | GlobeNewswire | +0.16% | -0.32% | |
| Form 10-Q Esperion Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.16% | -0.32% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - SKY | Press release | GlobeNewswire | +0.00% | +0.16% | |
| Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | +0.16% | |
| Form DEFA14A Esperion Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.16% | +0.32% | |
| Esperion to be Acquired by ARCHIMED | Press release | GlobeNewswire | +0.16% | -0.64% | |
| ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.00% | -0.32% | |
| Form 8-K Esperion Therapeutics, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.16% | |
| Form DEFA14A Esperion Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.03% | -0.03% | |
| Esperion to Report First Quarter 2026 Financial Results on May 7 | Press release | GlobeNewswire | -0.51% | -3.54% | |
| Form ARS Esperion Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.71% | -3.32% | |
| Form DEF 14A Esperion Therapeutics, For: Apr 16 | SEC filing · Form DEF | SEC EDGAR | +0.71% | -3.32% | |
| Form DEFA14A Esperion Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.71% | -3.32% | |
| Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics | Press release | GlobeNewswire | +3.81% | -2.67% | |
| Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) | Press release | GlobeNewswire | +3.81% | -2.67% | |
| Form 8-K Esperion Therapeutics, For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +3.81% | -2.67% | |
| Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.92% | +1.11% | |
| Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 | Press release | GlobeNewswire | +1.82% | -4.01% | |
| Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session | Press release | GlobeNewswire | -0.18% | +0.00% | |
| Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia | Press release | GlobeNewswire | +3.54% | +5.91% | |
| Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.24% | -13.46% | |
| Form 10-K Esperion Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.12% | -3.36% | |
| Form 8-K Esperion Therapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +2.24% | -13.46% | |
| HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease | Press release | Canada Newswire | +0.53% | -2.46% | |
| Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) | Press release | GlobeNewswire | -1.26% | -8.20% | |
| Form 8-K Esperion Therapeutics, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -1.26% | -8.20% | |
| Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 | Press release | GlobeNewswire | +0.45% | -0.90% | |
| Esperion to Participate in The 2026 Citizens Life Sciences Conference | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 | Press release | GlobeNewswire | +0.44% | +4.11% | |
| Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.43% | -2.30% | |
| Form 8-K Esperion Therapeutics, For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -8.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ESPR section they belong to.
Where else ESPR is measured.
ESPR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Blueprint Medicines Corporation (BPMC) | 401 | -0.03% | 46% |
| EDGE THERAPEUTICS (EDGE) | 401 | -0.05% | 41% |
| Novavax, Inc. (NVAX) | 400 | 0.00% | 48% |
| AMEDICA CORP COMMON STOCK (AMDA) | 397 | -1.09% | 31% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Esperion Therapeutics, Inc.'s median reaction calculated?
Every labeled ESPR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 401 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of ESPR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ESPR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.